Gamaleya Research Institute 
Welcome,         Profile    Billing    Logout  
  Products    Diseases    Products    Trials    News 


«12...4567891011121314...3132»
  • ||||||||||  Sputnik-V (Gam-COVID-Vac Lyo) / Gamaleya Research Institute
    Review, Journal:  Controversy surrounding the Sputnik V vaccine. (Pubmed Central) -  Nov 7, 2021   
    The Sputnik V COVID-19 vaccine is a member of the so-called vector vaccines and uses two different vectors (Ad26 priming and Ad5 boost) to reduce the risk of a reduction in the effectiveness of the vaccination...However, it is imperative to document the efficacy and safety of the Sputnik V vaccine in individuals with high pre-existing anti-Ad26 and Ad5-neutralizing antibody titres and in those under the age of 18 or older than 60 years and be certain that Sputnik V does not cause the rare development of immune thrombotic thrombocytopenia. It is hoped that the now widespread use of this vaccine will generate a large pragmatic real-world study with data accessible to anyone interested in verifying them.
  • ||||||||||  Sputnik-V (Gam-COVID-Vac Lyo) / Gamaleya Research Institute
    Journal:  Long Term Immune Response Produced by the SputnikV Vaccine. (Pubmed Central) -  Nov 4, 2021   
    This breadth of reactivity was still evident 90 days after the first dose of the vaccine, showing that the vaccine has induced a prolonged response. As evidenced by the activation of T cells, cellular immunity strongly suggests the high potency of the SputnikV vaccine against SARS-CoV-2 infection.
  • ||||||||||  Sputnik-V (Gam-COVID-Vac Lyo) / Gamaleya Research Institute
    BIOMARKERS OF INFLAMMATION AND IMMUNE REGULATION IN COVID-19 PATIENTS AND COVID 19 VACCINATED INDIVIDUALS (Hall B (1st Floor); Monitor 10) -  Nov 2, 2021 - Abstract #ACAAI2021ACAAI_937;    
    Methods 20 patients who had COVID-19 infection (10 men and 10 women, age 37.6±17.0 years, 124.9±27.5 days after the first symptoms) and 22 patients who were vaccinated with the COVID 19 vaccine Sputnik-V (8 men and 14 women, age 53.3±12.8 years, 38.5±2.6 days after the first vaccination) were assessed...There was also a decrease in the concentration of presepsin, LBP and an increase in procalcitonin in the serum of Sputnik-V vaccinated individuals compared with those who had had the COVID 19 infection (p <0.05). Conclusions COVID 19 infection and COVID 19 vaccination both induce immune changes including immunoregulatory and inflammatory biomarker changes with differences seen between COVID 19 vaccinated and COVID 19 infected patients.
  • ||||||||||  Sputnik-V (Gam-COVID-Vac Lyo) / Gamaleya Research Institute
    Clinical, Journal:  The social demographic aspects of vaccination of population of Russia in the context of COVID-19 pandemic (Pubmed Central) -  Oct 22, 2021   
    Also, significant increase of percentage of vaccinated population can be achieved if clearly defined requirements for availability of COVID-19 vaccination would be adopted on the international level. Actually, this is key condition for restoring international mobility and removing restrictions in national economies.
  • ||||||||||  Enrollment open:  ECEHeVac: Collaborative Study to Evaluate Heterologous Vaccination Against Covid-19 in Argentina (clinicaltrials.gov) -  Sep 28, 2021   
    P2,  N=1760, Recruiting, 
    A total of twelve new infections occurred within the first 3 months post-vaccination, eight after the first dose of BNT-162b2 and ChAdOx1-S (one each) and BBIBP-CorV (six), and four after full vaccination with BBIBP-CorV, but none required hospitalization. Not yet recruiting --> Recruiting
  • ||||||||||  Sputnik-V (Gam-COVID-Vac Lyo) / Gamaleya Research Institute
    Enrollment closed, Trial completion date, Trial primary completion date:  Sputnik-HD: Immune Response in Dialysis Patients Vaccinated Against COVID-19 (clinicaltrials.gov) -  Sep 27, 2021   
    P=N/A,  N=42, Active, not recruiting, 
    Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting | Trial completion date: Oct 2021 --> Jan 2022 | Trial primary completion date: Sep 2021 --> Jan 2022
  • ||||||||||  Vaxzevria (ChAdOx1-S recombinant) / Oxford Biomedica, Emergent Biosolutions, Jenner Institute, Vaccitech, AstraZeneca, University of Oxford, Sputnik-V (Gam-COVID-Vac Lyo) / Gamaleya Research Institute
    [VIRTUAL] Safety of COVID-19 vaccines in patients with multiple sclerosis from Latin America (ePoster Library) -  Sep 23, 2021 - Abstract #ECTRIMS2021ECTRIMS_2384;    
    COVID-19 vaccines seem to be safe for pwMS from Latin America. No major safety signals appeared in this patient-reported study.
  • ||||||||||  Sputnik-V (Gam-COVID-Vac Lyo) / Gamaleya Research Institute
    [VIRTUAL] Acute disseminated encephalomyelitis following vaccination against SARS-CoV-2: a case report (ePoster Library) -  Sep 23, 2021 - Abstract #ECTRIMS2021ECTRIMS_1560;    
    Our patient met the ADEM diagnostic criteria set by the International Pediatric MS Study Group and alternative diagnoses were excluded. Although a plausible relationship was not demonstrated, the possibility of an association with vaccine is suspected.